Perrigo Company PLC (NYSE:PRGO) EVP Grainne Quinn sold 2,050 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $49.08, for a total value of $100,614.00. Following the completion of the sale, the executive vice president now owns 3,047 shares in the company, valued at approximately $149,546.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of PRGO traded up $1.10 during mid-day trading on Friday, reaching $49.14. The company had a trading volume of 14,971 shares, compared to its average volume of 999,730. Perrigo Company PLC has a 52-week low of $36.28 and a 52-week high of $64.63. The company has a quick ratio of 1.32, a current ratio of 2.07 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $6.57 billion, a P/E ratio of 10.84, a PEG ratio of 4.88 and a beta of 1.46. The stock has a 50 day moving average of $53.21 and a two-hundred day moving average of $49.98.
Perrigo (NYSE:PRGO) last issued its earnings results on Wednesday, November 6th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.11. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.20 billion. Perrigo had a return on equity of 9.39% and a net margin of 5.24%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.09 earnings per share. On average, sell-side analysts expect that Perrigo Company PLC will post 3.96 earnings per share for the current year.
PRGO has been the topic of a number of recent research reports. ValuEngine upgraded Perrigo from a “sell” rating to a “hold” rating in a research note on Wednesday, September 11th. Wells Fargo & Co upped their target price on Perrigo from $45.00 to $52.00 and gave the stock a “market perform” rating in a research note on Monday, September 30th. TheStreet upgraded Perrigo from a “d+” rating to a “c-” rating in a research note on Friday, September 27th. SunTrust Banks upped their target price on Perrigo from $51.00 to $55.00 and gave the stock a “hold” rating in a research note on Wednesday, September 25th. They noted that the move was a valuation call. Finally, Argus upgraded Perrigo from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $54.17.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SRS Capital Advisors Inc. acquired a new position in Perrigo in the 2nd quarter worth about $25,000. Financial Gravity Wealth Inc. raised its holdings in Perrigo by 15,075.0% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 607 shares of the company’s stock worth $29,000 after purchasing an additional 603 shares during the period. Commonwealth Bank of Australia raised its holdings in Perrigo by 295.6% in the 2nd quarter. Commonwealth Bank of Australia now owns 890 shares of the company’s stock worth $42,000 after purchasing an additional 665 shares during the period. Parallel Advisors LLC raised its holdings in Perrigo by 343.3% in the 3rd quarter. Parallel Advisors LLC now owns 931 shares of the company’s stock worth $52,000 after purchasing an additional 721 shares during the period. Finally, CSat Investment Advisory L.P. raised its holdings in Perrigo by 43.1% in the 2nd quarter. CSat Investment Advisory L.P. now owns 1,527 shares of the company’s stock worth $72,000 after purchasing an additional 460 shares during the period. 87.89% of the stock is owned by institutional investors.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Recommended Story: How does the Beige Book influence monetary policy?
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.